Navigation Links
Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting
Date:12/4/2008

clinical trials.

    Title:       "Preliminary Results from a Phase II Trial of Triapine(R)
                  Plus Fludarabine for Adults with Aggressive
                  Myeloproliferative Disorders"
    Date:         Sunday, December 7
    Time:         9:00 a.m. to 8:00 p.m. (authors present 6:00-8:00 p.m.)
    Location:     Moscone Center Hall A, Board II-905

    Title:       "A Retrospective Comparison of Matched Elderly Patients
                 Treated with Laromustine (Cloretazine(R)) or Best
                 Supportive Care or Low-Dose Ara-C in the LRF AML14 Trial"
    Date:        Monday, December 8
    Time:        10:30 a.m. to 7:30 p.m. (authors present 5:30-7:30 p.m.)
    Location:    Moscone Center Hall A, Board III-42

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Onrigin(TM) (laromustine), formerly known as Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Onrigin(TM) (laromustine) with cytarabine in elderly patients with acute myelogenous leukemia, with standard remission-induction therapy in patients with AML and myelodysplatic syndromes (MDS), with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at '/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... -- Senior Vice President, General Manager for ... business acumen Elsevier , a world-leading ... services, congratulates Diane Bartoli , Senior Vice President ... Clinical Solutions, for being recognized in the 13 th ... of Profiles in Diversity Journal ® . ...
(Date:11/22/2014)... MA (PRWEB) November 21, 2014 ... key investors will gather on December 3rd at ... Biotech Conferences series. GeneticRx will take place at ... Medical School and will discuss the present and ... therapy, exon skipping, and gene editing—as well as ...
(Date:11/22/2014)... November 22, 2014 The “Chiral ... Preparative), by Material (Metal, Glass, Plastic), by Application ... SFC] - Forecast to 2018” analyses and studies ... in North America, Europe, Asia, and Rest of ... and 15 figures spread through 135 pages and ...
(Date:11/21/2014)... , Todd Martensen ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo empresarial ... en marcha para comenzar de forma rápida la comercialización de ... aprobación en Europa   , KLOX ... los siguientes nombramientos: Todd Martensen ha ...
Breaking Biology Technology:Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5
... SHENYANG, China, May 3, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio ... "the Company"), a leading China-based biotechnology company focused ... today announced that it will release its first ... stock market  closes on Wednesday, May 11, 2011 ...
... 3, 2011 At this year,s American Academy of AntiAging ... named the leading factors in premature aging and disease. AGEs ... result of sugar that attaches to a protein or lipid ... AGEs are completely irreversible—and cause accelerated damage to the tissues ...
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a ... diseases, announced today that after scientific review, the ongoing ... for multiple sclerosis (MS) has received an additional $1,594,553 ... Institute of Neurological Disorders and Stroke (NIH/NINDS). The clinical ...
Cached Biology Technology:3SBio Inc. Schedules Unaudited First Quarter 2011 Results 2At This Year's American Academy of AntiAging (A4M) Conference, Glycation and AGEs (Advanced Glycation End Products) Were Named the Leading Factors in Premature Aging and Disease 2Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 2Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 3Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 4
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... have found a way to project future habitat ... for threatened biodiversity. Associate Professor Grant Wardell-Johnson ... Institute for Biodiversity and Climate, along with lead ... now at Wageningen University in the Netherlands, developed ...
... on undersea vehicles that have fish-like sensations, advanced ship ... of Naval Research (ONR) on Dec. 23 learned they ... and engineers. The researchers have been selected for ... and will be honored at a ceremony at the ...
... in a quest to correct a faulty chromosome through cellular ... used stem cells to correct a defective "ring chromosome" with ... chromosome abnormalities that give rise to birth defects, mental disabilities ... be possible to use this approach to take cells from ...
Cached Biology News:Safe havens revealed for biodiversity in a changed climate 2White House lauds ONR-funded researchers for early success 2Nature study discovers chromosome therapy to correct a severe chromosome defect 2Nature study discovers chromosome therapy to correct a severe chromosome defect 3
... isoprostanes produced from arachidonic acid during lipid peroxidation. ... rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced platelet ... µM, respectively. When infused into the renal artery ... mg/kg/min, 8-iso PGE2 decreases the GFR and renal ...
... centrifuge offers both high-speed and high-volume ... of rotor options, making it ideal for ... Maximum Versatility , High-speed (up to ... or high-volume (4 x 250mL) swinging bucket ...
...
... submarine gel systems used gasketed gel trays. Turn the ... tank. Turn it back and run the gel - ... Turn & Cast tray is UV transparent. Each tray ... the tray and one in the center. This allows ...
Biology Products: